University of Nottingham-led speech therapy trial for PD shows improved results
The University of Nottingham in the UK has announced that a recent clinical trial has demonstrated the effectiveness of a…
Other Diseases
-
-
Aquestive maps out FDA approval for sublingual anaphylaxis drug
Aquestive Therapeutics has revealed topline data from the Phase III pharmacokinetic (PK) study of its anaphylactic drug, Anaphylm (epinephrine) sublingual…
-
J&J touts success of nipocalimab in two rare disease trials
Johnson & Johnson (J&J) has announced positive topline results for nipocalimab in two rare disease indications - generalised myasthenia gravis…
-
EASD 2023: meta-analysis shows tirzepatide superiority to semaglutide
At the 59th Annual European Association for the Study of Diabetes (EASD) 2023 meeting, a new meta-analysis has shown the…
-
Kashiv completes Phase I trial for Xolair biosimilar
US-based Kashiv Biosciences has successfully completed a Phase I trial for its Xolair biosimilar ADL018, the company’s latest biosimilar in…
-
FDA reviews protocol of NLS Pharmaceutics’ study of Mazindol ER
The US Food and Drug Administration (FDA) has reviewed the full protocol of NLS Pharmaceutics’ NLS-1031 study, which is part…
-
Chinook reports data from Phase I trial of CHK-336
Chinook Therapeutics has reported results from a Phase I trial evaluating CHK-336, an oral small molecule LDHA inhibitor, in development…
-
Mirum completes enrollment of Phase IIb trial for biliary atresia
Mirum has completed enrollment for its Phase IIb EMBARK study evaluating Livmarli (maralixibat) in infants with biliary atresia who have…
-
Omega-3 Fatty Acids May Reduce Risk of Chronic Kidney Disease
Chronic kidney disease (CKD) is a condition characterised by a gradual loss of kidney function over time, leading to the…
-
Pipeline Moves: Phase II cancer trial of Roche asset terminated, shot at further study drops
In this week’s Pipeline Moves, we start off with the termination of an investigator-led Phase II cancer study of Roche’s…
